<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="viruses-11-00807-t005" orientation="portrait" position="float">
 <object-id pub-id-type="pii">viruses-11-00807-t005_Table 5</object-id>
 <label>Table 5</label>
 <caption>
  <p>Summary of the selected VEEV IC INH-9813 strain in mice, nonhuman primates (NHPs), and humans.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"> </th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">BALB/c Mouse</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cynomolgus Macaque</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Humans (VEEV IC Strains)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Route of Exposure</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SC (scruff of neck);
     <break/>Aerosol (whole body)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aerosol (head only)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parenteral (mosquito-borne). No aerosol-acquired VEEV IC cases reported</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Disease and mortality</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lethal infection after SC and aerosol exposure due to encephalitis even at low challenge doses (100% mortality after 100 pfu challenge dose), with death or euthanasia 6–8 days after challenge [
     <xref rid="B71-viruses-11-00807" ref-type="bibr">71</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-lethal infection (100%) in 11 NHPs after aerosol challenge (dose range 5 × 10
     <sup>4</sup> to 5.94 × 10
     <sup>8</sup> pfu; 30 pfu in a single NHP) [
     <xref rid="B71-viruses-11-00807" ref-type="bibr">71</xref>] 
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1995 Colombia/Venezuela outbreak with VEE IC INH-9813 strain (mosquito-borne disease) [
     <xref rid="B6-viruses-11-00807" ref-type="bibr">6</xref>,
     <xref rid="B23-viruses-11-00807" ref-type="bibr">23</xref>].
     <break/>Generally non-lethal infection after SC exposure. No reported cases of aerosol-acquired VEEV IC.
     <break/>Infection common after exposure to low doses. Encephalitis uncommon; mainly in children/elderly
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Exposure Dose</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LD
     <sub>50</sub> SC =5 pfu;
     <break/>LD
     <sub>50</sub> aerosol = 53 pfu 
     <sup>a</sup>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ID
     <sub>50</sub> aerosol ≤ 30 pfu (
     <italic>n</italic> = 1)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low infective dose (human infective dose unknown)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Disease Onset</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48 h to 6 days</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 to 48 h</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.5 h to 4 days in 11 mosquito-borne VEE IC cases (strain unknown) [
     <xref rid="B5-viruses-11-00807" ref-type="bibr">5</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Clinical Manifestation</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV INH-9813 resulted in infection after SC and aerosol exposure (100% infection).
     <break/>Mice with infection demonstrated initial signs of decreased grooming and ruffled fur 6 days after SC challenge or 48 h after aerosol challenge, followed by lethargy, hunched posture, and hind-limb paralysis (likely due to encephalitis), with death or euthanasia 6–8 days after SC or aerosol challenge 
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV INH-9813 resulted in 100% infection after aerosol challenge.
     <break/>NHPs demonstrated initial signs of fever and lethargy 24–48 h after challenge, with fever resolving by D7. Biphasic fever noted only at highest dose tested. Tremors of variable duration (4–8 days; maximum 26 days) in 50% of NHPs. All NHPs survived
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mosquito-borne VEEV IC infection (strain unknown) similar to VEE IA/B infection in well-characterized outbreak in Texas (
     <italic>n</italic>-88) [
     <xref rid="B5-viruses-11-00807" ref-type="bibr">5</xref>]. Self-limiting febrile illness of 1-week duration (asthenia may persist for 1–2 weeks). Symptoms included high fever, chills, severe headache, myalgias, malaise, and anorexia. Also, nausea, vomiting, sore throat, photophobia, ocular pain, arthralgia, somnolence and drowsiness reported. Encephalitis in 2% adults (mild) and 7.6% children. Encephalitis manifested by decreased sensorium, disorientation, delirium, nuchal rigidity, ataxia, seizures; coma and paralysis in severe cases
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Clinical Laboratory</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viremia detected starting on D1–D2 post-challenge and resolved by D3–D4.
     <break/>Lymphopenia typically noted early in infection.
     <break/>Elevated WBC count detected later in some NHPs (
     <italic>n</italic> = 6)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEE IC outbreak (strain unknown) [
     <xref rid="B5-viruses-11-00807" ref-type="bibr">5</xref>]: Viremia documented in 40 cases from D0–D8 of illness (most common on D3 of illness).
     <break/>Lymphopenia (&lt;1490 cells/mm
     <sup>3</sup>) in 80% cases on D1–D4 of illness; increase generally on D4 with recovery by D9.
     <break/>Leukopenia (&lt;4500 cells/mm
     <sup>3</sup>) in 75% cases at D1–D2, (recovery of total WBC by D3/neutropenia by D6–D8)
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Pathology</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pathology studies not performed </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild to moderate lymphocytic perivascular cuffing with gliosis in CNS at day 28 post-challenge. No viral antigen detected in CNS</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Autopsy of 21 mosquito-borne VEEV IC cases (strain unknown): Cerebrovascular congestion (
     <italic>n</italic> = 14), edema with inflammatory infiltrates in brain/spinal cord (
     <italic>n</italic> = 17), intracerebral hemorrhage (
     <italic>n</italic> = 7), vasculitis (
     <italic>n</italic> = 4), meningitis (
     <italic>n</italic> = 13), encephalitis (
     <italic>n</italic> = 7), cerebritis (
     <italic>n</italic> = 5). Vasculitis, fibrin thrombi, perivascular hemorrhage and edema, occasional necrosis of blood vessel walls. Inflammatory infiltrates with lymphocytic and mononuclear cells, neutrophils, histiocytes. Lymph nodes and spleen with marked lymphoid depletion/follicular necrosis; hepatocellular degeneration and congestion (11/18 cases); interstitial pneumonia (19/21 cases) and pulmonary edema (11/21 cases) [
     <xref rid="B70-viruses-11-00807" ref-type="bibr">70</xref>] 
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>D = day; SC = subcutaneous. 
    <sup>a</sup> Starting concentration and all-glass impinger samples for aerosol exposure quantitated by plaque assay to determine titer (pfu/mL); Guyton and Bide formulas used to calculate the inhaled exposure dose per animal.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
